On January 13, 2021, Evoke Pharma, Inc. announced that during December 2020, the company, through its marketing partner, Eversana Life Science Services, LLC (Eversana), conducted an ATU (Awareness, Trial, and Usage) Study, a quantitative survey to measure physician awareness, trial, and product usage, for GIMOTI. Approximately 104 total physician responses were captured. Survey respondents were split into three groups drawn from the healthcare practitioner (HCP) community; target gastroenterologists currently being called on by the field sales force (n = 61), other non-target gastroenterologists (n = 19), and primary care physicians (PCPs) who are not currently targeted for messaging (n = 24). Areas of interest that were queried included initial and future potential prescribing trends, and how HCPs viewed the suitability of GIMOTI in certain gastroparesis patient populations. The results of the ATU survey may not predict prescribing trends by doctors or acceptance by patients, and are not intended to reflect or imply actual prescriptions or sales to date. Key Findings: Indicated an intent to prescribe GIMOTI: 79% of target gastroenterologists. 89% of non-target gastroenterologists. 50% of PCPs. Out of those target gastroenterologists indicating an intent to prescribe GIMOTI, 94% indicated GIMOTI would be appropriate to use in moderate to severe patients. A majority of each of the target and non-target gastroenterologists noted they intend to prescribe GIMOTI for both new and existing gastroparesis patients. Nineteen of all participating HCPs indicated that they have already written a prescription for GIMOTI. HCPs indicated that the primary driver for prescribing GIMOTI was patients being switched to GIMOTI due to lack of efficacy of current treatments.